Business
-
United Therapeutics has filed a patent infringement suit against Liquidia Technologies in the US District Court for the District of Delaware alleging infringement of US patents 9,604,901 and 9,593,066, which protect Tyvaso treprostinil inhalation solution. Both patents… Read more . . .
-
UCB said that it is paying $125 million up front, plus up to $145 million in potential milestone payments, to acquire Engage Therapeutics. Engage has a single candidate, Staccato inhaled alprazolam, which is in Phase… Read more . . .
-
Marinomed Biotech has announced that Fidia Farmaceutici will begin marketing Marinomed’s Carragelose-based nasal sprays in Italy in Fall 2020, and Sanova Pharma has signed an agreement to launch the new Carravin nasal spray in Austria… Read more . . .
-
Novus Therapeutics said that a Phase 2a clinical trial of its OP0201 intranasal surfactant MDI for the treatment of acute otitis media in infants and children failed to meet its primary endpoints of “resolution of… Read more . . .
-
Atossa Therapeutics announced that it has signed an agreement with Summit Biosciences for development and manufacturing of an intranasal formulation of Atossa’s AT-301 as a candidate for the treatment of mild COVID-19, and it plans… Read more . . .
-
Microbion Corporation said that it has received a grant worth up to $11.5 million from global non-profit CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and a grant worth up to $5.6 million from the Cystic Fibrosis… Read more . . .
-
Teva Canada said that it has imported a 4-week supply of Salamol salbutamol (albuterol) sulfate MDIs through Teva UK under an interim order by the Minister of Health in response to shortages of the inhalers in Canada caused… Read more . . .
-
Senzer Pharmaceuticals has announced the launch of a new Critical Care Division for development of two inhaled anti-viral drugs for the treatment of COVID-19. The company did not specify which drugs it planned to develop… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of its Airz-FF glycopyrronium/formoterol/fluticasone propionate triple combination inhaler for the treatment of COPD in India. The company said that “AIRZ-FF has been exclusively studied in the Indian population and introduced to… Read more . . .
-
DPI developer Iconovo has announced that Amneal will take over development of a generic version of Symbicort based on Iconovo’s multi-dose ICOres device. Iconovo and Amneal initially signed a licensing and development deal in 2016.… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA